Disease | ANCA |
Cystic fibrosis | c, p or aANCA often to BPI found in 32%26 |
Bronchogenic carcinoma | pANCA seen in non small cell lung cancer27 |
Mycobacterial infection | aANCA correlation uncertain28 |
Sarcoidosis | cANCA in 5%29 |
HIV | c or pANCA in 20%, MPO or PR3 positive30 |
Inflammatory bowel disease/Crohn's disease | p or aANCA, ulcerative colitis 60–75% and Crohn's disease 15–25%, usually lactoferrin not MPO31 |
Primary biliary cirrhosis | pANCA in 30–40%32 33 |
Autoimmune hepatitis | c or pANCA in 35–72%32 34 |
Sclerosing cholangitis | pANCA often to lactoferrin in 60–75%32-34 |
Amoebiasis | cANCA positive 97% (PR3 positive in 75%)35 |
Post streptococcal glomerulonephritis | p or aANCA in 9% occasionally MPO positive36 |
Chromomycosis | cANCA in 20% not to PR-337 |
Malaria | aANCA in 50% (anti-cathepsin-G Ab)38 |
Leprosy | c or pANCA positive in 17%39 |
Myeloproliferative disorders | pANCA positive in 40% (MPO positive 8%)40 |
Systemic lupus erythematosis | pANCA positive in 42%41 |
Juvenile chronic arthritis | c or pANCA not to PR3 or MPO42 |
Rheumatoid arthritis | pANCA positive most frequently to lactoferrin43 |
Chronic graft versus host disease | aANCA in 17%, no antigenic specificity44 |
ANCA = antineutrophil cytoplasmic antibody; cANCA = cytoplasmic ANCA; pANCA = perinuclear ANCA; aANCA = atypical ANCA; MPO = myeloperoxidase, PR-3 = proteinase 3; BPI = bacterial permeability increasing protein.